Emergent BioSolutions Initiates Phase I Study Evaluating Lassa Virus Vaccine Candidate

Emergent BioSolutions, Inc. announced that it has dosed the first participant in its Phase I study evaluating the safety and immunogenicity of EBS-LASV, a recombinant VSV-vectored Lassa virus vaccine candidate being developed for prevention of disease caused by Lassa virus infection.